CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...

Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...

GSK raised its full-year financial outlook despite mixed results from its vaccines segment and declining sales of Shingrix. The British pharma giant reported total quarterly sales of £7.9 billion, up ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...

LONDON, Jan 7 (Reuters) - GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory applications, it said on Wednesday, raising ...

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks.

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial ...

Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse portfolios. Bristol Myers is focused on discovering, developing and delivering ...

GSK (NYSE:GSK) shares snapped six straight sessions of gains, as the stock ended down 0.6% at $38.70 on Friday. The pharmaceutical giant added 3.6% in the preceding six sessions. The stock has gained ...